mavatrep
Small moleculeexperimental
Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist. It is an investigational analgesic that may be a potential treatment for pain and/or inflammation. — Wikipedia
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT01006304)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Vanilloid receptorANTAGONIST
TRPV1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(O)c1ccccc1-c1ccc2[nH]c(/C=C/c3ccc(C(F)(F)F)cc3)nc2c1- Mol. weight
- 422.45 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMavatrep ↗
- ChEMBLCHEMBL2364618 ↗
Also known as
- 2-(2-(2-(2-(4-trifluoromethylphenyl)vinyl)-1h-benzimidazol-5-yl)phenyl)propan-2-ol
- jnj-39439335
- jnj-39439335
- jnj-39439335
- mavatrep
- mavatrep
- mavatrep
- mavatrep
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01631487 | Phase 1 | Jul 1, 2012 | Johnson and Johnson |
| NCT01454245 | Phase 1 | Jul 1, 2011 | Johnson and Johnson |
| NCT01343303 | Phase 1 | Mar 1, 2011 | Johnson and Johnson |
| NCT00933582 | Phase 1 | Aug 1, 2009 | Johnson and Johnson |
| NCT01006304 | Phase 1 | Jun 1, 2009 | Johnson and Johnson |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 5 | 5 | 1 | 2009 |
1 organizations
Page 1 / 1